Home » Newsletters » BioWorld Science

BioWorld Science

April 14, 2011

View Archived Issues

Abbott presents new ROCK-2 inhibitor with high specificity and selectivity

First-in-human data reported on GDC-0973 alone and in combination with GDC-0941

Pfizer's new HSP 90 inhibitor PF-4942847 shows promise in triple-negative breast cancer in vivo

Levels of pentraxin-related protein PTX3 may predict unresponsiveness to IVIG in Kawasaki's disease

Vanderbilt University patents new modulators of metabotropic glutamate mGlu5 receptor

Israeli scientists present new DJ-1-related peptides for neurodegenerative diseases

Suven patents novel serotonin 5-HT4 receptor modulators

Recordati discloses novel metabotropic glutamate mGlu5 receptor antagonists

New 17-beta-HSD 3 inhibitors prepared by Sumitomo

Vernalis regains rights to adenosine A2A receptor antagonists from Biogen Idec

APEPTICO begins phase I AP-301 trial in pulmonary edema

FDA sets PDUFA date for Teva Pharma's Bio-T-Gel NDA

PharmAthene completes dosing in phase I Valortim trial for inhalational anthrax

Intellect Neurosciences files FDA orphan drug application for OX-1 in Friedreich's ataxia

Cellmid and Antitope to collaborate on humanization of midkine-directed antibodies

Myriad Genetics to conduct mutation testing for BioMarin's phase I/II BMN-673 trial

4SC grants Yakult Honsha license to resminostat in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...